NCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT00354302 2020-04-02
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
Canadian Cancer Trials Group
Phase 3 Completed
NCT00485953 2017-10-13
REBBeCA II
University of Pittsburgh
Phase 4 Completed
NCT00054418 2016-07-13
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00859703 2013-10-31
RISAROS
Hospices Civils de Lyon
Phase 3 Completed
NCT00324714 2012-11-29
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
ETOP IBCSG Partners Foundation
Phase 3 Withdrawn
NCT00082277 2011-01-26
SABRE
AstraZeneca
Phase 4 Completed